Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refr...
Gespeichert in:
| Veröffentlicht in: | Blood Jg. 124; H. 8; S. 1259 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
21.08.2014
|
| Schlagworte: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Imexon was administered at 1000 mg/m(2) IV daily for 5 days in 21-day cycles. Gene expression analysis performed on pretreatment tumor specimens included 13 transcripts used to generate a redox signature score, previously demonstrated to correlate with lymphoma prognosis. Twenty-two patients were enrolled having follicular (n = 9), diffuse large B-cell (DLBCL) (n = 5), mantle cell (n = 3), transformed follicular (n = 2), small lymphocytic (n = 2), and Burkitt (n = 1) lymphoma. The most common grade 3/4 adverse events were anemia (14%) and neutropenia (9%). The overall response rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5). Gene expression analyses revealed CD68 and the redox-related genes, GPX1 and SOD2, as well as a higher redox score to correlate with clinical responses. Therefore, pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This trial was registered at www.clinicaltrials.gov as #NCT01314014. |
|---|---|
| AbstractList | Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Imexon was administered at 1000 mg/m(2) IV daily for 5 days in 21-day cycles. Gene expression analysis performed on pretreatment tumor specimens included 13 transcripts used to generate a redox signature score, previously demonstrated to correlate with lymphoma prognosis. Twenty-two patients were enrolled having follicular (n = 9), diffuse large B-cell (DLBCL) (n = 5), mantle cell (n = 3), transformed follicular (n = 2), small lymphocytic (n = 2), and Burkitt (n = 1) lymphoma. The most common grade 3/4 adverse events were anemia (14%) and neutropenia (9%). The overall response rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5). Gene expression analyses revealed CD68 and the redox-related genes, GPX1 and SOD2, as well as a higher redox score to correlate with clinical responses. Therefore, pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This trial was registered at www.clinicaltrials.gov as #NCT01314014.Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Imexon was administered at 1000 mg/m(2) IV daily for 5 days in 21-day cycles. Gene expression analysis performed on pretreatment tumor specimens included 13 transcripts used to generate a redox signature score, previously demonstrated to correlate with lymphoma prognosis. Twenty-two patients were enrolled having follicular (n = 9), diffuse large B-cell (DLBCL) (n = 5), mantle cell (n = 3), transformed follicular (n = 2), small lymphocytic (n = 2), and Burkitt (n = 1) lymphoma. The most common grade 3/4 adverse events were anemia (14%) and neutropenia (9%). The overall response rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5). Gene expression analyses revealed CD68 and the redox-related genes, GPX1 and SOD2, as well as a higher redox score to correlate with clinical responses. Therefore, pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This trial was registered at www.clinicaltrials.gov as #NCT01314014. Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Imexon was administered at 1000 mg/m(2) IV daily for 5 days in 21-day cycles. Gene expression analysis performed on pretreatment tumor specimens included 13 transcripts used to generate a redox signature score, previously demonstrated to correlate with lymphoma prognosis. Twenty-two patients were enrolled having follicular (n = 9), diffuse large B-cell (DLBCL) (n = 5), mantle cell (n = 3), transformed follicular (n = 2), small lymphocytic (n = 2), and Burkitt (n = 1) lymphoma. The most common grade 3/4 adverse events were anemia (14%) and neutropenia (9%). The overall response rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5). Gene expression analyses revealed CD68 and the redox-related genes, GPX1 and SOD2, as well as a higher redox score to correlate with clinical responses. Therefore, pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This trial was registered at www.clinicaltrials.gov as #NCT01314014. |
| Author | Casulo, Carla Miller, Thomas P Persky, Daniel O Spier, Catherine M Barr, Paul M Fisher, Richard I Roe, Denise J Peterson, Derick R Herr, Megan Rimsza, Lisa M Schwartz, Mark Landowski, Terry H Baran, Andrea M Briehl, Margaret M Friedberg, Jonathan W Littleton, Jamie Dorr, Robert T Puvvada, Soham Bernstein, Steven H Cui, Haiyan |
| Author_xml | – sequence: 1 givenname: Paul M surname: Barr fullname: Barr, Paul M organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 2 givenname: Thomas P surname: Miller fullname: Miller, Thomas P organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 3 givenname: Jonathan W surname: Friedberg fullname: Friedberg, Jonathan W organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 4 givenname: Derick R surname: Peterson fullname: Peterson, Derick R organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 5 givenname: Andrea M surname: Baran fullname: Baran, Andrea M organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 6 givenname: Megan surname: Herr fullname: Herr, Megan organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 7 givenname: Catherine M surname: Spier fullname: Spier, Catherine M organization: Department of Pathology, University of Arizona, Tucson, AZ – sequence: 8 givenname: Haiyan surname: Cui fullname: Cui, Haiyan organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 9 givenname: Denise J surname: Roe fullname: Roe, Denise J organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 10 givenname: Daniel O surname: Persky fullname: Persky, Daniel O organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 11 givenname: Carla surname: Casulo fullname: Casulo, Carla organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 12 givenname: Jamie surname: Littleton fullname: Littleton, Jamie organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 13 givenname: Mark surname: Schwartz fullname: Schwartz, Mark organization: HTG Molecular Diagnostics, Inc., Tucson, AZ; and – sequence: 14 givenname: Soham surname: Puvvada fullname: Puvvada, Soham organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 15 givenname: Terry H surname: Landowski fullname: Landowski, Terry H organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 16 givenname: Lisa M surname: Rimsza fullname: Rimsza, Lisa M organization: Department of Pathology, University of Arizona, Tucson, AZ – sequence: 17 givenname: Robert T surname: Dorr fullname: Dorr, Robert T organization: University of Arizona Cancer Center, Tucson, AZ – sequence: 18 givenname: Richard I surname: Fisher fullname: Fisher, Richard I organization: Fox Chase Cancer Center, Temple University, Philadelphia, PA – sequence: 19 givenname: Steven H surname: Bernstein fullname: Bernstein, Steven H organization: University of Rochester, Wilmot Cancer Center, Rochester, NY – sequence: 20 givenname: Margaret M surname: Briehl fullname: Briehl, Margaret M organization: Department of Pathology, University of Arizona, Tucson, AZ |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25016003$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAURYMozof-A5EsXUz0JWnabnVQRxjQha5Lmrw61TSpTQvTf2_FEVy9e-FwObwFOfbBIyEXHK45z8VN6UKwTABPGCRMZQBJckTmXImcAQg4_pdnZBHjB0ysFOqUzIQCngLIOaledjoiFTT2gx1pqGjd4D74FdW07ULY11b7njbBoRkcrmjtaYdOtxEt1d5Opeq06UM30jtm0Dk6ebJNsO-fE-rGpt2FRp-Rk0q7iOeHuyRvD_ev6w3bPj8-rW-3zCSp7JnNQZos1aXkfEol55VUZVbpXOYorFHcQma0kSWqrEQwVqc5JlwoazG1SizJ1e_u5P41YOyLpo4_VtpjGGLBlVKpSCBPJ_TygA5lg7Zou7rR3Vj8_UZ8A71baeY |
| CitedBy_id | crossref_primary_10_1007_s13402_023_00884_9 crossref_primary_10_3389_fimmu_2020_01538 crossref_primary_10_1155_2016_6235641 crossref_primary_10_1182_bloodadvances_2019000527 crossref_primary_10_1016_j_tranon_2016_04_007 crossref_primary_10_1097_MD_0000000000024598 crossref_primary_10_3389_fphar_2019_00728 crossref_primary_10_1097_MD_0000000000015811 crossref_primary_10_3390_molecules29071430 crossref_primary_10_1002_pst_2067 crossref_primary_10_1016_j_xkme_2025_101050 crossref_primary_10_1186_s40001_025_02955_z crossref_primary_10_3109_10520295_2016_1142610 crossref_primary_10_3390_antiox12040936 crossref_primary_10_1007_s10555_022_10077_9 crossref_primary_10_1182_blood_2016_03_705814 crossref_primary_10_1097_MOH_0000000000000351 crossref_primary_10_1002_ccr3_7361 crossref_primary_10_1186_s12964_015_0118_6 crossref_primary_10_1016_j_critrevonc_2018_05_014 crossref_primary_10_1136_jitc_2022_005503 crossref_primary_10_18632_oncotarget_13559 crossref_primary_10_3389_fonc_2022_862743 crossref_primary_10_3390_molecules23010045 crossref_primary_10_1152_physrev_00037_2024 crossref_primary_10_1186_s43556_025_00261_y crossref_primary_10_3390_antiox14030264 crossref_primary_10_3390_antiox10111801 crossref_primary_10_1158_2159_8290_CD_21_0558 |
| ContentType | Journal Article |
| Copyright | 2014 by The American Society of Hematology. |
| Copyright_xml | – notice: 2014 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2014-04-570044 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 25016003 |
| Genre | Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA130805 – fundername: NCI NIH HHS grantid: P01 CA017094 – fundername: NCI NIH HHS grantid: CA-130805 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 AALRI ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c463t-d803c76ab31103cb11f35b7fa838e2dc51d07cac3be57be0cda68e4125dde6d52 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 31 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000342761900017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Sep 28 09:46:28 EDT 2025 Thu Apr 03 07:06:56 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | 2014 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c463t-d803c76ab31103cb11f35b7fa838e2dc51d07cac3be57be0cda68e4125dde6d52 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2014-04-570044 |
| PMID | 25016003 |
| PQID | 1555624086 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1555624086 pubmed_primary_25016003 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-Aug-21 20140821 |
| PublicationDateYYYYMMDD | 2014-08-21 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-Aug-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2014 |
| SSID | ssj0014325 |
| Score | 2.3007493 |
| Snippet | Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to manipulations of the cellular... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1259 |
| SubjectTerms | Adult Aged Aged, 80 and over Biomarkers, Tumor - biosynthesis Disease-Free Survival Female Gene Expression Regulation, Neoplastic - drug effects Glutathione Peroxidase - biosynthesis Glutathione Peroxidase GPX1 Hexanones - administration & dosage Hexanones - adverse effects Humans Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - metabolism Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology Male Middle Aged Neoplasm Proteins - biosynthesis Oxidants - administration & dosage Oxidants - adverse effects Oxidative Stress - drug effects Recurrence Superoxide Dismutase - biosynthesis Survival Rate |
| Title | Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25016003 https://www.proquest.com/docview/1555624086 |
| Volume | 124 |
| WOSCitedRecordID | wos000342761900017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB5868VHfb-IIJ4M7W42m-1JVBQPWnpQ6K3kqUW7W22V9t87yW7xJAhell3IsiGZzPdtZjIfwKnUCONcc5r6Up9JmiiqRCZx4VlhjWyyRIUirvei1co6nWa72nAbVmmVU58YHLUptN8jryPuIVQnyMAvBu_Uq0b56GoloTEL8wypjLdq0fmJIiQsiK4iRGXU86Lq6BxS6nqZFo7oF9IwQpH35HeSGcDmdu2_3VyH1YpmksvSLjZgxuY12LzM8Re7PyFnJCR-hh31GixeTe-Wr6fybzVYeqii7pvg2i-IdSQmoRYtKRzp9e24yM-JJNi9YtwzOD-kXyrt2nPSy4k_IzMYWkNkbvDBfQRdnwm5oj5UQPIip3eFeX7Fpm8TtKiiL7fg6fbm8fqOVvoMVCcpG1GTNZgWqVQMOQTTKooc40o4mbHMxkbzyDSElpopy4WyDW1kmtkEKRX61NTweBvm8HN2F4jlXKeOR0y6po8wK41EtmldauPYKCb24GQ63F0cB99Tmdvic9j9GfA92CnnrDsoC3V0kd5FSOjY_h_ePoCV0hrQcUSHMO9w9dsjWNBfo97w4zgYFl5b7YdvFGrXdA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+2+study+of+imexon%2C+a+prooxidant+molecule%2C+in+relapsed+and+refractory+B-cell+non-Hodgkin+lymphoma&rft.jtitle=Blood&rft.au=Barr%2C+Paul+M&rft.au=Miller%2C+Thomas+P&rft.au=Friedberg%2C+Jonathan+W&rft.au=Peterson%2C+Derick+R&rft.date=2014-08-21&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=124&rft.issue=8&rft.spage=1259&rft_id=info:doi/10.1182%2Fblood-2014-04-570044&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |